Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: a map of the current evidence
Methylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric o...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 September 2019
|
| In: |
Neuroscience & biobehavioral reviews
Year: 2019, Volume: 107, Pages: 945-968 |
| ISSN: | 1873-7528 |
| DOI: | 10.1016/j.neubiorev.2019.09.023 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.neubiorev.2019.09.023 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0149763419302350 |
| Author Notes: | Helga Krinzinger, Charlotte L Hall, Madeleine J Groom, Mohammed T Ansari, Tobias Banaschewski, Jan K Buitelaar, Sara Carucci, David Coghill, Marina Danckaerts, Ralf W Dittmann, Bruno Falissard, Peter Garas, Sarah K Inglis, Hanna Kovshoff, Puja Kochhar, Suzanne McCarthy, Peter Nagy, Antje Neubert, Samantha Roberts, Kapil Sayal, Edmund Sonuga-Barke, Ian C K Wong, Jun Xia, Alessandro Zuddas, Chris Hollis, Kerstin Konrad, Elizabeth B Liddle, the ADDUCE Consortium |
| Summary: | Methylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes. We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of long-term MPH (> 1year) treatment in ADHD. We coded studies using a “traffic light” system: Green: safe/favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were coded as “Unclear”. Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD. Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at risk for substance misuse. We identified a need for more studies that make use of large longitudinal databases, focus on specific neuropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter or no pharmacological intervention. |
|---|---|
| Item Description: | Gesehen am 18.03.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1873-7528 |
| DOI: | 10.1016/j.neubiorev.2019.09.023 |